ADB-BUTINACA (ADB-B) Finished Product – High-Purity Research Chemical for Forensic Analysis

ADB-BUTINACA (commonly abbreviated as ADB-B) is a potent synthetic indazole-based cannabinoid belonging to the latest generation of Novel Psychoactive Substances (NPS). As a finished product, this material is presented in its final, ready-to-analyze form exclusively for forensic, toxicological, and advanced chemical research. Our ADB-BUTINACA is characterized by its exceptional analytical purity (>98%), providing researchers, law enforcement agencies, and reference laboratories with an unequivocal standard for the identification and quantification of this compound in unknown samples.

This compound is of critical importance for public health monitoring and forensic science, enabling the study of its structure, metabolism, and impact on the endocannabinoid system in vitro. It is supplied strictly as a non-human, non-diagnostic research chemical for use in controlled laboratory environments.

Key Features & Advantages:

• Uncompromising Purity for Definitive Identification: Synthesized and purified to achieve a minimum of >98% purity, as rigorously verified by orthogonal analytical methods (HPLC-DAD, GC-MS, NMR). This high purity is essential to prevent analytical interference and ensure accurate research results.

• Complete Analytical Documentation: Each batch is accompanied by an extensive Certificate of Analysis (CoA) that includes detailed chromatograms (HPLC/GC-MS), spectral data (NMR, FTIR), and mass confirmation, providing full traceability and definitive proof of structure and purity.

• Critical Forensic Reference Standard: This finished product is intended solely for use as a certified reference material (CRM) by forensic laboratories for the unambiguous identification of ADB-BUTINACA in seized materials, biological samples, and clinical case studies.

• Enhanced Stability Packaging: Packaged under an inert argon atmosphere within light-resistant, hermetically sealed glass vials to protect against thermo-oxidative degradation and ensure long-term stability and integrity.

• Batch-to-Batch Consistency: Produced in controlled, single-batch syntheses to guarantee homogeneity and reliable, reproducible performance across all research applications, from metabolic pathway identification to receptor affinity studies.

Chemical Specifications:

• Systematic Name: N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3-carboxamide

• Common Names: ADB-BUTINACA; ADB-B; ADBB

• CAS Number: 2361286-67-2

• Molecular Formula: C₁₈H₂₆N₄O₂

• Molecular Weight: 330.43 g/mol

• Appearance: White to light beige crystalline or powdery solid.

• Purity: ≥98% (HPLC)

• Solubility: Soluble in dimethyl sulfoxide (DMSO), ethanol, and methanol; sparingly soluble or insoluble in water.

Mechanism of Action (Research Context):

ADB-BUTINACA is a high-potency, high-efficacy full agonist of the human cannabinoid receptors CB1 and CB2. In research models, it demonstrates a significantly higher binding affinity and functional potency than Δ9-THC. Its primary research value lies in its utility for:

• Receptor Binding Studies: Determining binding affinity (Ki) and understanding competitive interactions at cannabinoid receptors.

• Functional Pharmacological Assays: Measuring agonist-induced receptor activation (e.g., GTPγS binding, cAMP accumulation assays) to calculate efficacy (EC50) and intrinsic activity.

• Metabolic Profiling: Identifying in-vitro and in-vivo phase I and phase II metabolites using human liver microsomes or hepatocytes, which is crucial for developing targeted toxicological screens.

Applications & Intended Use:

This product is a finished research chemical intended exclusively for non-human, in-vitro research applications in controlled, accredited laboratory environments.

Its primary applications include:

• Forensic Toxicology & Crime Lab Analysis: Serves as a critical reference standard for the definitive identification and quantification of ADB-BUTINACA in seized drug evidence, facilitating prosecution and public health surveillance.

• Clinical Toxicology & Harm Reduction: Used by research institutions and hospitals to develop and validate analytical methods (HPLC-MS/MS, GC-MS) for detecting this substance in human biological samples (blood, urine) in cases of overdose and adverse events.

• Pharmacological Research: Utilized in academic settings to study the structure-activity relationships (SAR) of synthetic cannabinoids, their potent effects on the endocannabinoid system, and the mechanisms behind their severe toxicity.

• Metabolic Studies: Essential for in-vitro studies aimed at mapping the unique metabolic pathways of ADB-BUTINACA to identify characteristic biomarker metabolites.

Packaging & Storage:

To preserve the integrity of this potent and sensitive compound, it is packaged with the highest level of care:

• Primary Container: Sealed within a clear glass vial with a PTFE/silicone septum to ensure an airtight environment.

• Protective Packaging: The vial is housed within a light-resistant, vacuum-sealed foil bag.

• Inert Atmosphere: Vial headspace is purged with inert argon gas before sealing to prevent oxidation.

• Desiccant: Includes a desiccant pack to control moisture.

• Standard Sizes: Typically available in small milligram quantities (e.g., 100mg, 250mg, 500mg) suitable for analytical reference purposes.

Storage Conditions: MUST be stored frozen at -20°C ± 5°C for long-term stability. Keep the container tightly sealed and protected from light at all times. Store in a secure, access-controlled facility compliant with local regulations for controlled substance analogues.

Quality & Compliance:

Every batch is produced in a dedicated research facility adhering to a strict quality assurance protocol. The comprehensive Certificate of Analysis (CoA) provides full analytical traceability and is essential for forensic accreditation and method validation.